D
David Hendlin
Researcher at Merck & Co.
Publications - 53
Citations - 2397
David Hendlin is an academic researcher from Merck & Co.. The author has contributed to research in topics: Cephamycin & Cefoxitin. The author has an hindex of 23, co-authored 53 publications receiving 2327 citations.
Papers
More filters
Journal ArticleDOI
Effect of methionine, norleucine, and lysine derivatives on cephalosporin c formation in chemically defined media
TL;DR: The final medium supported the production of approximately 0.5 g of cephalosporin C per liter of medium and stimulation of antibiotic production was obtained with the lysine derivatives epsilon-N-acetyl-l-lysine and ePSilon-aminocaproic acid but not with lysines itself.
Journal ArticleDOI
Cephamycins, a New Family of β-Lactam Antibiotics: Antibacterial Activity and Resistance to β-Lactamase Degradation
TL;DR: The susceptibility to some cephalosporin antibiotics and to cephamycin C, a member of a new family of β-lactam antibiotics, was evaluated for 466 cultures representing 11 different genera or species of gram-negative clinical isolates.
Journal ArticleDOI
Cefoxitin and Cephamycins: Microbiological Studies
TL;DR: The therapeutic effectiveness of cefoxitin in experimental infections in mice confirms the excellent characteristics of this semisynthetic cephamycin and indicates that it should be a very valuable agent for treatment of bacterial infections.
Journal ArticleDOI
Azirinomycin. I. Microbial production and biological characteristics.
Journal ArticleDOI
Cephamycins, a New Family of β-Lactam Antibiotics. III. In Vitro Studies
TL;DR: Cephamycin C protected mice against β-lactamase-producing Proteus cultures, including clinically isolated strains, and had good in vivo gram-negative activity, comparing favorably with cEPhalothin and cephaloridine against cepHalosporin-susceptible organisms.